Elevated levels of circulating CD44 in patients with systemic sclerosis: Association with a milder subset

Rheumatology

Volumn 41, Issue 10, 2002, Pages 1149-1154

  Komura, K ^a   Sato, S ^a   Fujimoto, M ^b   Hasegawa, M ^a   Takehara, K ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

Limited cutaneous systemic sclerosis; Longitudinal study; Pulmonary fibrosis; Soluble CD44

Indexed keywords

CELL ADHESION MOLECULE; HERMES ANTIGEN; PENICILLAMINE; PREDNISOLONE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; LEUKOCYTE MIGRATION; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHOOL CHILD; SYSTEMIC SCLEROSIS;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD44; BIOLOGICAL MARKERS; CHILD; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PULMONARY FIBROSIS; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SOLUBILITY;

EID: 0036798295     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. White B. Immunopathogenesis of systemic sclerosis. Rheum Dis Clin North Am 1996;32:695-708.
2. Furst DE, Clements PJ. Hypothesis for the pathogenesis of systemic sclerosis. J Rheumatol 1997;24(Suppl. 48):53-7.
3. Sato S. Abnormalities of adhesion molecules and chemokines in scleroderma. Curr Opin Rheumatol 1999; 11:503-7.
4. Springer TA. Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration. Annu Rev Physiol 1995;57:827-72.
5. Butcher EC. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell 1991; 67:1033-6.
6. DeLisser HM, Newman PJ, Albelda SM. Molecular and functional aspects of PECAM-1/CD31. Immunol Today 1994;15:490-5.
7. Ihn H, Sato S, Fujimoto M, Takehara K, Tamaki K. Increased serum levels of soluble vascular cell adhesion molecule-1 and E-selectin in patients with systemic sclerosis. Br J Rheumatol 1998;37:1188-92.
8. Denton CP, Bickerstaff MCM, Shiwen X et al. Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis. Br J Rheumatol 1995; 34:1048-54.
9. Stratton RJ, Coghlan JG, Pearson JD et al. Different patterns of endothelial cell activation in renal and pulmonary vascular disease in scleroderma. Q J Med 1998;91:561-6.
10. Sato S, Komura K, Hasegawa M, Fujimoto M, Takehara K. Clinical significance of soluble CD31 in patients with systemic sclerosis (SSc): Association with limited cutaneous SSc. J Rheumatol 2001;28:2460-5.
11. Drillenburg P, Pals ST. Cell adhesion receptors in lymphoma dissemination. Blood. 2000;95:1900-10.
12. DeGrendele HC, Estess P, Siegelman MH. Requirement for CD44 in activated T cell extravasation into an inflammatory site. Science 1997;278:672-5.
13. Haynes BF, Hale LP, Patton KL, Martin ME, McCallum RM. Measurement of an adhesion molecule as an indicator of inflammatory disease activity. Up-regulation of the receptor for hyaluronate (CD44) in rheumatoid arthritis. Arthritis Rheum 1991;34:1434-43.
14. Mikecz K, Brennan FR, Kim JH, Glant T. Anti-CD44 treatment abrogates tissue oedema and leukocyte infiltration in murine arthritis. Nature Med 1995; 1:558-63.
15. Estess P, DeGrendele HC, Pascual V, Siegelman MH. Functional activation of lymphocyte CD44 in peripheral blood is a marker of autoimmune disease activity. J Clin Invest 1998;102:1173-82.
16. Guo YJ, Liu G, Wang X et al. Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer. Cancer Res 1994;54:422-6.
17. Martin S, Jansen F, Bokelmann J, Kolb H. Soluble CD44 splice variants in metastasizing human breast cancer. Int J Cancer 1997;74:443-5.
18. De Rossi G, Marroni P, Paganuzzi M et al. Increased serum levels of soluble CD44 standard, but not of variant isoforms v5 and v6, in B cell chronic lymphocytic leukemia. Leukemia 1997;11:134-41.
19. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
20. LeRoy EC, Krieg T, Black C et al. Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 1988;15:202-5.
21. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
22. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975;292:344-7.
23. Steen VD, Powell DL, Medsger TAJ. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988;31:196-203.
24. Sato S, Ihn H, Kikuchi K, Takehara K. Antihistone antibodies in systemic sclerosis: association with pulmonary fibrosis. Arthritis Rheum 1994;37:391-4.
25. Kahaleh MB, Osborn I, LeRoy EC. Increased factor 8/von Willebrand factor and von Willebrand activity in scleroderma and in Raynaud's phenomenon. Ann Intern Med 1981;94:482-4.
26. Shi-Wen X, Panesar M, Vancheeswaran R et al. Expression and shedding of intercellular adhesion molecule 1 and lymphocyte function-associated antigen 3 by normal and scleroderma fibroblasts. Effects of interferon-gamma, tumor necrosis factor alpha, and estrogen. Arthritis Rheum 1994;37:1689-97.
27. Koch EK, Kronfeld-Harrington LB, Szekanecz Z et al. In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Pathobiology 1993;61:239-46.
28. Liao F, Ali J, Greene T, Muller WA. Soluble domain 1 of platelet-endothelial cell adhesion molecule (PECAM) is sufficient to block transendothelial migration in vitro and in vivo. J Exp Med 1997;185:1349-57.
29. Goldberger A, Middleton KA, Oliver JA et al. Biosynthesis and processing of the cell adhesion molecule PECAM-1 includes production of a soluble form. J Biol Chem 1994;269:17183-91.
30. Mikecz K, Dennis K, Shi M, Kim JH. Modulation of hyaluronan receptor (CD44) function in vivo in a murine model of rheumatoid arthritis. Arthritis Rheum 1999; 42:659-68.
31. Rothmann BL, Blue M-L, Kelley KA, Wunderlich D, Mierz DV, Anne TM. Human T cell activation by OKT3 is inhibited by a monoclonal antibody to CD44. J Immunol 1991;147:2493-9.
32. Verdrengh M, Holmdahl R, Tarkowski A. Administration of antibodies to hyaluronan receptor (CD44) delays the start and ameliorates the severity of collagen II arthritis. Scand J Immunol 1995;42:353-8.
33. Sollberg S, Peltonen J, Uitto J, Jimenez SA. Elevated expression of beta 1 and beta 2 integrins, intercellular adhesion molecule 1, and endothelial leukocyte adhesion molecule 1 in the skin of patients with systemic sclerosis of recent onset. Arthritis Rheum 1992;35:290-8.
34. Watson SR, Fennie C, Lasky LA. Neutrophil influx into an inflammatory site inhibited by a soluble homing receptor-IgG chimera. Nature 1991;349:164-7.
35. Gamble JR, Skinner MP, Berndt MC, Vadas MA. Prevention of activated neutrophil adhesion to endothelium by soluble adhesion protein GMP. Science 1990; 249:414-7.